Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8NI17
UPID:
IL31R_HUMAN
Alternative names:
Cytokine receptor-like 3; GLM-R; Gp130-like monocyte receptor; ZcytoR17
Alternative UPACC:
Q8NI17; A6NIF8; Q2TBA1; Q6EBC3; Q6EBC4; Q6EBC5; Q6EBC6; Q6UWL8; Q8WYJ0
Background:
The Interleukin-31 receptor subunit alpha, also known as Cytokine receptor-like 3, GLM-R, Gp130-like monocyte receptor, and ZcytoR17, plays a pivotal role in the immune system. It forms a receptor with OSMR that activates STAT3, STAT1, and STAT5, influencing skin immunity and mediating IL31-induced itch. This receptor is crucial for the survival and proliferation of myeloid progenitor cells in bone marrow.
Therapeutic significance:
Given its involvement in primary localized cutaneous amyloidosis, understanding the role of Interleukin-31 receptor subunit alpha could open doors to potential therapeutic strategies. Targeting this receptor may offer new avenues for treating skin-related amyloidosis, emphasizing the importance of further research in this area.